GL1X · GenesisL1 explorer

MolNFT v1 · #137916 · protein

1.80A resolution structure of human IGG3 Fc (N392K)

5W38 · Immunoglobulin heavy constant gamma 3: “1.80A resolution structure of human IGG3 Fc (N392K)”. X-ray diffraction, 2 ligands (NAG, BMA), 1 pocket (best druggability 0.30). MolNFT v1 #137916 on GenesisL1: 3D structure, binding sites…

PDB
5W38
Type
protein
Length
418 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Immunoglobulin heavy constant gamma 3
UniProt
P01860
Ligands
NAG, BMA
Pockets
1 · best druggability 0.30

Structure

x-ray diffraction · 2 distinct chains · 11% helix, 47% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AImmunoglobulin heavy constant gamma 3protein20911% helix, 47% strandP01860
BImmunoglobulin heavy constant gamma 3protein20910% helix, 47% strandP01860

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 4 copies · chains A, B
  • BMA · beta-D-mannopyranose · sugar · 2 copies · chains A, B
  • FLC · Citrate anion · additive · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1640.300.7517empty

Interfaces

1 interface between chains.

  • A–B · 1192 Ų buried · 7 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide, 2 glycan (disulfide, N-glycosylation).

Compared structures

  • 5W38 · 1.80A resolution structure of human IgG3 Fc (N392K) · the same entry in another collection · chain A against A, TM-score 1.00
  • P01860 · AlphaFold monomer V2.0 prediction for immunoglobulin heavy constant gamma 3 (P01860) · a predicted model of the same protein · chain B against A, TM-score 0.89

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.